Essential Tremor

Multi-Contact Probe Provides Alternative to Pharmaceutical and Invasive Surgical Treatments Submission Completed Earlier Than Anticipated EDEN PRAIRIE, Minn., April 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has filed its 510(k) submission to the FDA for trigeminal nerve ablation earlier than previous guidance. This submission leverages the Company’s proprietary OneRF® Ablation System RF generator platform for the treatment of trigeminal neuralgia, a chronic pain condition affecting approximately 100,000 people in the U.S.1. The trigeminal nerve is the main sensory nerve in the face associated with triggering excruciating pain for this condition. Trigeminal neuralgia is typically treated with medication or invasive procedures, including microvascular decompression (MCD), radiosurgery, or other percutaneous techniques. The OneRF® Trigeminal Nerve Ablation technology features a minimally invasive surgical procedure that uses radiofrequency (RF) energy to destroy abnormal tissue to relieve severe, chronic pain in the face. Differentiated features of this multi-contact probe are designed to use multi-point mapping of pain location, stimulation and ablation, all using the same electrode and with the safety of temperature-controlled ablation. These features are also present in the FDA 510(k) cleared OneRF sEEG (brain) Ablation System. This system may allow for reduced procedural time, improved patient comfort and improved patient safety. Previously published data have shown that RF ablation offers high initial pain relief rates (~95%) and long-term efficacy, especially with repeat treatments, while maintaining a low complication rate2,3, These characteristics make it a preferred option for patients who are not candidates for major surgery or who are looking for less invasive approaches4. Dave Rosa, President and CEO of NeuroOne, stated: “Our OneRF® ablation technology platform has already achieved successful commercialization and patient outcomes in lesioning nerve tissue for functional neurosurgical procedures, such as the treatment of epilepsy. Expanding into facial pain broadens the clinical impact of our technology and further validates the versatility and scalability of our platform.” “If cleared by the FDA, we believe there is a potential to generate revenues from trigeminal nerve ablation in late calendar year 2025.” NeuroOne’s OneRF® ablation technology has garnered significant media interest, including recent features on Fox News and Good Morning America. For more interviews and information on the company, please visit www.nmtc1.com. About NeuroOne NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com. Forward Looking Statements This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “forecasts,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the potential to receive 510(k) clearance for our trigeminal nerve ablation system, the potential to receive revenue from the commercialization of our trigeminal nerve ablation program in 2025 or at all, our business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations for the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future. Caution: Federal law restricts this device to sale by or on the order of a physician. IR ContactMZ Group – MZ North AmericaNMTC@mzgroup.us 1 American Association of Neurological Surgeons (AANS) - April 2024 2 Kanpolat Y et al. Percutaneous controlled radiofrequency trigeminal rhizotomy for the treatment of idiopathic trigeminal neuralgia: 25-year experience with 1,600 patients. Neurosurgery. 2001 Mar;48(3):524-32;. doi: 10.1097/00006123-200103000-00013. 3 Wang Z et al. Radiofrequency thermocoagulation for the treatment of trigeminal neuralgia. Exp Ther Med. 2022 Jan;23(1):17. doi: 10.3892/etm.2021.10939. 4 Emril DR, Ho KY. Treatment of trigeminal neuralgia: role of radiofrequency ablation. J Pain Res. 2010 Dec 12;3:249-54.doi: 10.2147/JPR.S14455.

No Surgery. No Scalpels. No Recovery Time. Tremors Gone in Minutes. MIAMI, April 22, 2025 /PRNewswire/ -- For millions living with Essential Tremor (ET), simple tasks like eating, writing, or holding a drink can feel impossible. Now, the Miami Neuroscience Center at Larkin is offering a revolutionary solution: Focused Ultrasound — a non-invasive, FDA-approved treatment delivering immediate relief without surgery or recovery time. Led by internationally renowned neurosurgeon Dr. Aizik Wolf, this state-of-the-art procedure is changing lives in real time. "We're seeing patients walk out of treatment tremor-free within hours," said Dr. Wolf, Medical Director at Miami Neuroscience Center. "The transformation is instant and life-changing." Why This Matters Essential Tremor affects over 10 million Americans. Until now, treatment options included invasive brain surgery or lifelong medications. Focused Ultrasound is a game-changer: No scalpels, cuts, or anesthesia FDA Approved MRI-guided precision Outpatient procedure — patients go home with results the same day Covered by Medicare and most major insurance plans This cutting-edge technology uses targeted sound waves to treat the area of the brain responsible for tremors — with no incisions or implants required. Real People. Real Results. "I couldn't hold a cup of coffee without spilling. After the procedure, I signed my name for the first time in 15 years." — Patient testimonial, Miami Neuroscience Center Watch the Transformation Spanish Video Version Before & After View Media Access Interviews available with: Dr. Aizik Wolf Dr. Jose Valerio Real patients with before-and-after success stories High-res images and video upon request Schedule a Consultation or Learn More: Call: (786) 871-6806 Email: [email protected] About Miami Neuroscience Center at Larkin Part of Larkin Health System, the Miami Neuroscience Center is a state-of-the-art facility offering advanced, patient-focused care for neurological conditions including brain tumors, AVMs, herniated discs, migraines, trigeminal neuralgia, and more. Treatments include Focused Ultrasound , Gamma Knife®, Zap-X®, and Airo® technology. Learn more: CONTACT: Frances Rodriguez | Marketing Director | [email protected] SOURCE Miami Neuroscience Center at Larkin WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Company Now Fully Funded Through at least Fiscal 2026; Company Confirms No Material Impact from Global Tariffs EDEN PRAIRIE, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has issued a letter to shareholders from CEO, Dave Rosa. Dear Shareholders, In recent months, NeuroOne has achieved several significant milestones, including the expansion of our commercial partnership with Zimmer Biomet, progress towards the submission of a 510(k) filing to treat facial pain, and continued product development momentum in areas of back pain management and drug delivery. Most notably, the expansion of our partnership with Zimmer Biomet included exclusive distribution rights in the United States and certain additional countries for the OneRF® Ablation System, which is the first and only FDA-cleared product that uses the same sEEG electrode for both diagnostic and therapeutic applications. The agreement included an upfront license payment of $3.0 million in November 2024 as well as established pricing and required product minimums. Given the recent discussions around tariffs and global trade policy, we have also received questions regarding potential impacts on our supply chain. Investors should know that all of our key components are sourced and manufactured within the United States. Having a domestic-focused supply chain has been an intentional part of our operational strategy, and we do not anticipate any meaningful impact from current or proposed tariffs. To execute on the opportunities in front of us, last week we successfully completed a capital raise with institutional investors totaling $8.3 million in net proceeds. Despite significant volatility across the broader capital markets, the offering was oversubscribed by well-respected financial institutions, did not include prohibitive and future dilutive financing mechanisms, and reflects continued institutional interest in our technology platform and long-term strategy. With the proceeds from this offering, we believe the Company is now fully funded to operate through at least the end of fiscal year 2026, based on Zimmer making the minimum purchase requirements set forth in our expanded agreement. While our near-term focus remains on disciplined execution, if we achieve some of the key milestones currently in progress, we believe this capital could bring us to cash flow breakeven and support our long-term growth plans with no need for additional dilutive financing. For instance, in March 2025, we accelerated the anticipated timeline of our 510(k) submission to the FDA for trigeminal nerve ablation to May 2025, which leverages the OneRF® Technology Platform and will be used to create radiofrequency lesions for the treatment of pain, or for lesioning nerve tissue for functional neurosurgical procedures. With an estimated 100,000-200,000 patients suffering from facial pain in the U.S. alone, this market represents a significant opportunity for NeuroOne. Other areas of growth include the Spinal Cord Stimulation (SCS) Percutaneous Paddle Lead Program and the sEEG-Based Drug Delivery Program. Both are solutions that utilize the OneRF® platform for pain management and drug delivery, respectively. We are in advanced discussions with strategic partners which would further validate our technology, provide significant reach, and potentially, include upfront payments. Today, we stand as a larger, more mature company than ever before as we ramp revenues and product margins. We have a world class strategic partner, the necessary capital to execute on our strategic growth initiatives and several upcoming milestones that present significant opportunities to grow shareholder value. As we look ahead, we are reiterating our fiscal year 2025 guidance, with product revenues expected to increase to between $8.0-$10.0 million, representing an increase of between 132%-190% when compared to product revenue of $3.5 million in fiscal year 2024, and expanded product gross margin of between 47%-51%, compared to product gross margin of 31% in fiscal year 2024. Thank you for your unwavering support and being part of the NeuroOne story as we work to drive significant shareholder value and execute on the opportunities ahead of us. Sincerely, Dave RosaPresident & CEO About NeuroOne NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com. Forward Looking Statements This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “forecasts,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the Company’s ability to be fully-funded through 2026; the continued development of the Company’s electrode technology program (including its drug delivery program and spinal cord stimulation program); the ability to achieve cash-flow break-even without additional dilutive financing; fiscal year 2025 guidance, including expectations for significant product revenue growth and margin expansion; the plan to submit a 510(k) application with the FDA in May 2025 for the Company’s trigeminal nerve ablation program; business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that it has a reasonable basis for each forward-looking statement, the Company cautions you that these statements are based on a combination of facts and factors currently known by the Company and its expectations of the future, about which the Company cannot be certain. Actual future results may be materially different from what the Company expects due to factors largely outside of its control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements; risks that Zimmer may not purchase the minimum purchase requirements; risks that the Company’s strategic partnerships may not facilitate the commercialization or market acceptance of its technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that the Company’s technology will not perform as expected; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that the Company may not be able to secure or retain coverage or adequate reimbursement for its technology; uncertainties inherent in the development process of the Company’s technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that the Company may not have accurately estimated the size and growth potential of the markets for its technology; risks that the Company may be unable to protect its intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future. Caution: Federal law restricts this device to sale by or on the order of a physician. IR ContactMZ Group – MZ North AmericaNMTC@mzgroup.us